Annalee Armstrong is a Senior Editor at Fierce Pharma. She specializes in medicine and healthcare, with a focus on pharmaceuticals, pharmaceutical manufacturing, and regulation, as well as global markets. Annalee's work has been featured in outlets such as RamaOnHealthcare, Biotech, NewsBreak, BioSpace, and the Kimberley Bulletin.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Annalee Armstrong's coverage heavily focuses on the healthcare and pharmaceutical industry, particularly in biotech, drug discovery, fundraising, pharmaceutical companies, and clinical trials. Her articles often cite data or press releases.
If you're looking to reach out to Annalee with a pitch, consider offering access to exclusive data or insights related to developments within the biotech and pharmaceutical sectors. This could include information about new clinical trials, fundraising efforts by healthcare companies or breakthroughs in drug discovery.
It's important for sources reaching out to Annalee Armstrong to provide fact-based evidence that supports their pitches as it aligns with her focus on citing data in her articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Heather-Mckenzie, Gabrielle-Masson
Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma's top paid CEOs make up to 358 times more than their employees; Revolution Medicine's pancreatic cancer results highlight movement in the deadly disease space; more.
By: Annalee Armstrong
Lilly met analysts' sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist retatrutide in a highly anticipated readout on Thursday.
Biotech has been pulling off some remarkable science of late, while M&A and IPOs return to bolster the sector. But that doesn't mean the industry is back from the brink. BioSpace gathered three early-stage biotech CEOs and members of the NextGen Class of 2026 to talk about surviving and thriving in this rollercoaster market, all while bringing forward the next generation of medicines.
By: Annalee Armstrong
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
Eli Lilly, with a busier-than-ever business development team, has made a major vaccine play‚ months after hiring veteran vaccine regulator Peter Marks following his FDA departure.
From Eli Lilly's David Ricks to Pfizer Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
By: Annalee Armstrong, Jef Akst, Gabrielle Masson
Eli Lilly continues to spend its GLP-1 landfall with four new deals in the past week, including three in the vaccine space; the obesity leader also touted surgery-like results for its next-gen weight loss drug; Moderna's stock climbs on the hantavirus “fear trade”; and in oncology, all eyes are on Revolution at ASCO this week.
By: Annalee Armstrong
FDA veteran Peter Marks will now shape the future of Eli Lilly's vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
By: Annalee Armstrong
Apogee's pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
By: Annalee Armstrong
As Summit Therapeutics' Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
